With the aim to identify more specific targeted molecule for GC therapy, we screened all of the genetic mutations in the GC genome based on TCGA data sets and picked out seven most common mutational genes, which included MYC, MET, KRAS, MST1, NRAS, HRAS and TP53. Here, HRAS is linked to gastric cancer.